Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study-Reference-Cited by-同舟云学术

Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study

Published:2018-02-23 Issue:6 Volume:20 Page:1453-1460
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Aronson Ronnie¹^ORCID,Frias Juan²^ORCID,Goldman Allison³^ORCID,Darekar Amanda⁴,Lauring Brett⁵^ORCID,Terra Steven G.⁶^ORCID

Affiliation:

1. LMC Diabetes and Endocrinology; East York Canada

2. National Research Institute; Los Angeles California

3. Pfizer, Inc.; Collegeville Pennsylvania

4. Pfizer Ltd.; Tadworth UK

5. Merck & Co., Inc.; Kenilworth New Jersey

6. Pfizer, Inc.; Andover Massachusetts

Funder

Pfizer, Inc.

Merck

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.13251/fullpdf

Reference17 articles.

1. SGLT2 inhibitors: benefit/risk balance;Scheen;Curr Diab Rep,2016

2. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects;Ferrannini;Nat Rev Endocrinol,2012

3. Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin;Amin;Diabetes Obes Metab,2015

4. Blood pressure-lowering effect of the sodium glucose co-transporter-2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension;Amin;Diabetes Obes Metab,2015

5. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET)

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Transporter Proteins as Therapeutic Drug Targets—With a Focus on SGLT2 Inhibitors;International Journal of Molecular Sciences;2024-06-25

2. Therapy of Type 2 Diabetes;Experimental and Clinical Endocrinology & Diabetes;2024-04-10

3. Therapie des Typ-2-Diabetes;Die Diabetologie;2024-01-30

4. Longitudinal efficacy of Ertugliflozin in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials;Expert Opinion on Pharmacotherapy;2023-11-17

5. The impact of sodium-glucose Cotransporter-2 inhibitors on lipid profile: A meta-analysis of 28 randomized controlled trials;European Journal of Pharmacology;2023-11